Zolgensma, a lifesaving treatment for infants and the world’s most expensive drug, has been used to treat 100 patients since its launch and brought in $160 million for its maker Novartis last quarter, beating analysts’ expectations.
The gene therapy is a treatment for spinal muscular atrophy, a rare and devastating neurological disease. It carries a record price tag of $2.1 million, or an annualized cost of $425,000 per year for five years.
